- Home
- GAIN vs CELC Comparison
GAIN vs CELC Comparison
Compare GAIN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- CELC
- Stock Information
- Founded
- GAIN 2005
- CELC 2011
- Country
- GAIN United States
- CELC United States
- Employees
- GAIN N/A
- CELC N/A
- Industry
- GAIN Finance: Consumer Services
- CELC Medical Specialities
- Sector
- GAIN Finance
- CELC Health Care
- Exchange
- GAIN Nasdaq
- CELC Nasdaq
- Market Cap
- GAIN 550.0M
- CELC 440.0M
- IPO Year
- GAIN 2005
- CELC 2017
- Fundamental
- Price
- GAIN $14.07
- CELC $11.60
- Analyst Decision
- GAIN Hold
- CELC Strong Buy
- Analyst Count
- GAIN 2
- CELC 5
- Target Price
- GAIN $13.50
- CELC $30.80
- AVG Volume (30 Days)
- GAIN 185.2K
- CELC 135.3K
- Earning Date
- GAIN 08-04-2025
- CELC 08-13-2025
- Dividend Yield
- GAIN 10.74%
- CELC N/A
- EPS Growth
- GAIN N/A
- CELC N/A
- EPS
- GAIN 1.78
- CELC N/A
- Revenue
- GAIN $93,662,000.00
- CELC N/A
- Revenue This Year
- GAIN $6.09
- CELC N/A
- Revenue Next Year
- GAIN $3.93
- CELC N/A
- P/E Ratio
- GAIN $7.85
- CELC N/A
- Revenue Growth
- GAIN 7.28
- CELC N/A
- 52 Week Low
- GAIN $11.42
- CELC $7.58
- 52 Week High
- GAIN $15.34
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- GAIN 45.40
- CELC 49.88
- Support Level
- GAIN $14.01
- CELC $11.85
- Resistance Level
- GAIN $14.50
- CELC $13.40
- Average True Range (ATR)
- GAIN 0.29
- CELC 0.70
- MACD
- GAIN -0.07
- CELC -0.09
- Stochastic Oscillator
- GAIN 12.41
- CELC 35.83
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.